Will changes in primary care improve health outcomes? Modelling the impact of financial incentives introduced to improve quality of care in the UK

被引:42
作者
McElduff, P
Lyratzopoulos, G
Edwards, R
Heller, RF
Shekelle, P
Roland, M
机构
[1] Univ Manchester, Evidence Populat Hlth Unit, Sch Med, Sch Epidemiol & Hlth Sci, Manchester M13 9PT, Lancs, England
[2] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA
[3] Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester, Lancs, England
来源
QUALITY & SAFETY IN HEALTH CARE | 2004年 / 13卷 / 03期
关键词
D O I
10.1136/qshc.2003.007401
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To estimate the total health gain from improving the quality of care among patients with cardiovascular disease in line with the quality indicator targets in the new contract for general practitioners (GPs) in the UK. Design: Statistical modelling, applying population impact measures to estimate cardiovascular health gains from achieving treatment targets in the GP contract, taking into account current levels of treatment and control. Main outcome measures: Number of events prevented in the population over 5 years applied to a notional general practice population of 10 000. Results: The greatest health gain in those aged 45-84 years would come from reaching cholesterol reduction targets. This could prevent 15 events in people with coronary heart disease, seven events in those with a history of stroke, and seven events in those with diabetes. Achieving blood pressure control targets in hypertensive patients without the above conditions could prevent 15 cardiovascular events, with further benefits from reducing blood pressure in patients with high blood pressure and coronary heart disease, stroke, or diabetes. Achieving other targets would have smaller impacts because high levels of care are already being achieved or because of the low prevalence of conditions or associated event risk. Conclusion: It is possible to quantify the health gain to a practice population of achieving quality targets such as those set in the new GP contract. The amount of health gain is sensitive to current quality of care, prevalence of conditions, and risk factors, and to the size of change anticipated. Nevertheless, it appears that significant health gains could result from achieving the proposed quality targets.
引用
收藏
页码:191 / 197
页数:7
相关论文
共 33 条
[21]   SYSTEMATIC UNDERESTIMATION OF ASSOCIATION BETWEEN SERUM-CHOLESTEROL CONCENTRATION AND ISCHEMIC-HEART-DISEASE IN OBSERVATIONAL STUDIES - DATA FROM THE BUPA STUDY [J].
LAW, MR ;
WALD, NJ ;
WU, T ;
HACKSHAW, A ;
BAILEY, A .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6925) :363-366
[22]   BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .1. PROLONGED DIFFERENCES IN BLOOD-PRESSURE - PROSPECTIVE OBSERVATIONAL STUDIES CORRECTED FOR THE REGRESSION DILUTION BIAS [J].
MACMAHON, S ;
PETO, R ;
CUTLER, J ;
COLLINS, R ;
SORLIE, P ;
NEATON, J ;
ABBOTT, R ;
GODWIN, J ;
DYER, A ;
STAMLER, J .
LANCET, 1990, 335 (8692) :765-774
[23]   Commentary: Relative treatment effects are consistent across the spectrum of underlying risks ... usually [J].
McAlister, FA .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2002, 31 (01) :76-77
[24]   Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: Data from 3 health plans [J].
Nordin, J ;
Mullooly, J ;
Poblete, S ;
Strikas, R ;
Petrucci, R ;
Wei, FF ;
Rush, B ;
Safirstein, B ;
Wheeler, D ;
Nichol, KL .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (06) :665-670
[25]   The effect of spironolactone on morbidity and mortality in patients with severe heart failure [J].
Pitt, B ;
Zannad, F ;
Remme, WJ ;
Cody, R ;
Castaigne, A ;
Perez, A ;
Palensky, J ;
Wittes, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) :709-717
[26]  
*PRACT INC PROGR, OUTL PRACT INC PROGR
[27]   Systematic review of studies of quality of clinical care in general practice in the UK, Australia and New Zealand [J].
Seddon, ME ;
Marshall, MN ;
Campbell, SM ;
Roland, MO .
QUALITY IN HEALTH CARE, 2001, 10 (03) :152-158
[28]   Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure [J].
Sharma, D ;
Buyse, M ;
Pitt, B ;
Rucinska, EJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (02) :187-192
[29]   IMPACT OF INFLUENZA ON MORTALITY IN RELATION TO AGE AND UNDERLYING DISEASE, 1967-1989 [J].
SPRENGER, MJW ;
MULDER, PGH ;
BEYER, WEP ;
VANSTRIK, R ;
MASUREL, N .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1993, 22 (02) :334-340
[30]  
*STOCKP NHS TRUST, 2002, HLTH CAR PAT HF EV R